BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 15, 2011
View Archived Issues
New model developed to evaluate pharmacodynamics of antimicrobial agents and design dosing regimens
Read More
Phase III data presented on long-term safety and tolerability of degarelix in prostate cancer
Read More
Novartis profiles achievements of 2010
Read More
Lucentis improves vision in patients with diabetic macular edema in phase III RISE trial
Read More
Oxigene and NCI collaborate on phase II Zybrestat trial in ovarian cancer
Read More
Enrollment begins in Diamyd's phase II NP2 enkephalin trial in cancer pain
Read More
Ginseng metabolite S-111 has potent antidepressant effects in vivo
Read More
SMB recommends continuation of Vical's phase III Allovectin-7 trial in metastatic melanoma
Read More
Abbott identifies novel inhibitors of Cdc7
Read More
Gold nanoshells with silica nanorattle cores combine photo- and chemotherapy to treat cancer
Read More
Axcan Pharma acquires Eurand
Read More
DMC recommends continuation of phase III ThermoDox HEAT trial
Read More
Bayer Schering claims new [18F]-labeled PET imaging agents
Read More
Novel autotaxin inhibitors claimed
Read More
Beta Pharma patents new activators of hypoxia-inducible factor 1
Read More
Kamada receives interim report of phase II/III trial of inhaled alpha-1 antitrypsin
Read More
NurOwn autologous adult stem cell product receives FDA orphan drug status in ALS
Read More
PROLOR's phase II trial of long-acting human growth hormone proceeds as planned
Read More
Polaris and LICR begin phase II trial of ADI-PEG 20 in SCLC
Read More
Tarsa completes phase III trial of oral calcitonin in osteoporosis
Read More
Marina Biotech provides update on development of oligonucleotide-based therapeutics
Read More
Endpoint met in first part of phase II trial of Reolysin and gemcitabine in pancreatic cancer
Read More
